LitAlert ~~ GeneLit.com

    • Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers.
    • Huang CC, Tsai YF, Liu CY, Lien PJ, Lin YS, Chao TC, Feng CJ, Chen YJ, Lai JI, Phan NN, Hsu CY, Chiu JH, Tseng LM.
    • Ann Surg Oncol. 2022 Feb 28. doi: 10.1245/s10434-022-11347-0. Epub ahead of print.
    • Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer with Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-arm Study Authors.
    • Zhou D, Liu J, Liu R, Li H, Huang Y, Ma D, Hong L, Gao Q.
    • Front Oncol. 2022 Feb 28;10:852772. doi: 10.3389/fonc.2022.852772.
    • Incidence and Prevalence of Intraductal Papillary Mucinous Neoplasms in Individuals With BRCA1 and BRCA2 Pathogenic Variant.
    • Shah I, Silva-Santisteban A, Germansky KA, Wadhwa V, Tung N, Huang DC, Kandasamy C, Mlabasati J, Bilal M, Sawhney MS.
    • J Clin Gastroenterol. 2022 Feb 28. doi: 10.1097/MCG.0000000000001683. Epub ahead of print.
    • The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
    • Francis KE, Kim SI, Friedlander M, Gebski V, Coquard IR, Clamp A, Penson RT, Oza A, Perri T, Huzarski T, Martin-Lorente C, Cecere SC, Colombo N, Ataseven B, Fujiwara K, Sonke G, Vergote I, Pujade-Lauraine E, Kim JW, Lee CK.
    • Ann Oncol. 2022 Feb 24:S0923-7534(22)00338-6. doi: 10.1016/j.annonc.2022.02.222. Epub ahead of print.
    • Inibidores da PARP: do mecanismo de ação à prática clínica [PARP Inhibitors: From the Mechanism of Action to Clinical Practice].
    • Branco C, Paredes J.
    • Acta Med Port. 2022 Feb 1;35(2):135-143. Portuguese. doi: 10.20344/amp.13870. Epub 2022 Feb 1.